Figure 5. ¹⁷⁷Lu-4A06 and ²²⁵Ac-4A06 inhibit tumor growth in animal models of pancreatic cancer.

A. An antitumor assessment study in which mice bearing subcutaneous HPAC tumors received a single bolus of ¹⁷⁷Lu-4A06 (800 μCi/mouse), vehicle, or unlabeled 4A06. ¹⁷⁷Lu-4A06 significantly suppressed tumor growth compared vehicle or 4A06 alone (n = 8/treatment arm, *P<0.01) B. Tumor growth curves summarizing the antitumor effects of a single bolus of ¹⁷⁷Lu-4A06 (500 μCi) or two doses of ¹⁷⁷Lu-4A06 (250 μCi/dose) over seven days. Mice bearing subcutaneous HPAC tumors were treated. Only the fractionated dose significantly inhibited tumor growth compared to the vehicle treatment arm (n = 8/treatment arm). C. A Kaplan Meier curve showing that either dosing regimen extended survival compared to mice receiving vehicle. Statistical significance was determined using a Mantel-Cox log rank test. *P <0.05. D. A plot showing the percent change in body weight for mice receiving vehicle or ¹⁷⁷Lu-4A06. Neither dosing strategy resulted in dropout due to >20% loss of body weight. E. A tumor growth curve summarizing the effects of ²²⁵Ac-4A06 on the growth of subcutaneous HPAC tumors. A single intravenous injection of ²²⁵Ac-4A06 (0.8 μCi/mouse) significantly delayed tumor growth compared to mice receiving vehicle (n = 8/treatment arm). F. A Kaplan Meier curve showing that ²²⁵Ac-4A06 extended survival compared to mice receiving vehicle. Statistical significance was determined using a Mantel-Cox log rank test. *P < 0.05. The median survival of the vehicle group was 15 days, while the median survival of the treated group was 22 days. The log rank hazard ratio was 2.56 (95% CI = 0.8 – 7.6). G. A plot showing the average percent change in body weight for mice receiving vehicle or ²²⁵Ac-4A06. No mice dropped from the study due to an unsafe loss of body weight.